2020-06-13T01:24:56Zhttps:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi
oai:pubmedcentral.nih.gov:40596062014-06-16nihpapmc-openmanuscript
101305410 34612 J Infect Dev Ctries J Infect Dev Ctries Journal of infection in developing countries 2036-6590 1972-2680 PMC4059606 PMC4059606 4059606 21252450 21252450 nihpa579502 Article Salmonella enterica Serovars Typhi and Paratyphi A are avirulent in newborn and infant mice even when expressing virulence plasmid genes of Salmonella Typhimurium Javier Santander M. Curtiss Roy III The Biodesign Institute, Centre for Infectious Diseases and Vaccinology. Arizona State University, Tempe, Arizona Corresponding author: Roy Curtiss III, The Biodesign Institute, Center for Infectious Diseases and Vaccinology, Arizona State University, PO Box 875401, 1001 S. McAllister Avenue. Tempe, AZ 85287-5401, Phone: 480-727-0445, Fax: 480-727-0466, rcurtiss@asu.edu 19 5 2014 24 11 2010 11 2010 16 6 2014 4 11 723 731 Copyright © 2010 Santander and Curtiss. 2010 This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background

Salmonella enterica serovars Typhi and Paratyphi A are human host-restricted pathogens. Therefore, there is no small susceptible animal host that can be used to assess the virulence and safety of vaccine strains derived from these Salmonella serovars. However, infant mice have been used to evaluate virulence and colonization by another human host-restricted pathogen, Vibrio cholerae.

Methodology

The possibility that infant mice host could be adapted for Salmonella led us to investigate the susceptibility of newborn and infant mice to oral infection with S. Typhi and S. Paratyphi A. Salmonella enterica serovar Typhimurium causes enteric fever in adult mice and this system has been used as a model for human typhoid. The pSTV virulence plasmid, not present in S. Typhi and S. Paratyphi A, plays an essential role in S. Typhimurium colonization and systemic infection of mice. We also conjugated pSTV into S. Typhi and S. Paratyphi A serovars and evaluated these transconjugants in newborn and infant mice.

Results

We determined that the spv virulence genes from the S. Typhimurium virulence plasmid are expressed in S. Typhi and S. Paratyphi A in a RpoS dependent fashion. Also, we determined that S. Typhi and S. Paratyphi A with and without pSTV transiently colonize newborn and infant mice tissues.

Conclusion

Newborn and infant mice infected with S. Typhi and S. Paratyphi A do not succumb to the infection and that carriage of the S. Typhimurium virulence plasmid, pSTV, did not influence these results.

Salmonella Typhi Salmonella Paratyphi A newborn mice infant mice virulence plasmid
Introduction

Typhoid and paratyphoid fever are severe human diseases caused by S. Typhi and S. Paratyphi A respectively, with an estimated 16 million cases resulting in more than 600,000 deaths annually [1,2]. Both S. Typhi and S. Paratyphi A are human host-restricted pathogens. The pathogenesis of typhoid and paratyphoid are poorly understood, in part due to the lack of a susceptible animal host that exhibits the same clinical signs as human infections. Attenuated S. Typhi strains have been used as live vectors to deliver foreign antigens either by expressing antigens or by delivering the antigen-encoding genes on eukaryotic expression plasmids [3,4,5]. The absence of an inexpensive, small animal host for pre-clinical evaluation of vaccine candidates is an obstacle to developing live attenuated S. Typhi vaccines. Chimpanzees infected with wild-type S. Typhi Ty2 produced a mild clinical illness that resembled human typhoid fever, but only when given in a high dose (1x1011 CFU) [6]. This host is not convenient for high through-put analyses due to the high cost and scarcity of supply. In addition, since a high inoculum of wild-type is needed to cause clinical infection, this is not an ideal host for evaluating the virulence potential of attenuated strains [7].

S. Typhi and S. Paratyphi A are unable to induce progressive disease in adult BALB/c mice challenged orally or parenterally with high doses ( > 109 orally; 107 to 108 parenterally) [8,9,10,11,12]. The current method for assessing the safety of S. Typhi vaccines consists of inoculating mice intraperitoneally with moderated doses ( > 103 CFU) of S. Typhi suspended in hog gastric mucin [7]. However, death of the mice is believed to result from the toxic effects of endotoxin associated with the rapidly expanding peritoneal population of S. Typhi [13,14,15]. In addition, the attenuating effects of some mutations cannot be discerned by this method [16]. The use of other animal hosts, such as rabbits and pigs, has also been explored, but these animals were found to be no more useful than mice [17, 18]. However, intranasal inoculation of mice has been used successfully to evaluate the immune responses to foreign antigens expressed by S. Typhi recombinant vaccines [19,20].

S. Typhimurium, the causative agent of enterocolitis infection in humans and cattle, causes a lethal systemic disease in susceptible mice that resembles human typhoid infection [21,22]. The mouse assay has been adopted and extensively used to study pathogenesis and immunity of typhoid fever. However, a shortcoming of this assay is the fact that S. Typhimurium does not cause typhoid fever in humans, suggesting that genetic differences between S. Typhi and S. Typhimurium are critically important for the disease outcome in both mice and humans. Whole-genome sequencing has revealed genome degradation in host-restricted Salmonella serotypes [23]. Therefore, the evolution from a broad host range serovar such as Typhimurium, to host-restricted serovars such as Typhi and Paratyphi A, may have occurred by genome degradation [21,23]. In addition, not all the information obtained using the S. Typhimurium mouse assay can be directly applied to improve understanding of typhoid fever since some of the virulence factors of S. Typhimurium such as Salmonella virulence plasmid pSTV, required for invasion of host tissues [24,25], are absent in S. Typhi and S. Paratyphi A [23,26,27,28].

Nevertheless, infant mice have been used to measure the median lethal dose (LD50) as a parameter for disease production by Vibrio cholerae and other host-restricted bacterial strains [29,30,31] and therefore may be useful in developing a systemic infection model for S. Typhi and S. Paratyphi A, since adult mice are resistant to those pathogens [10]. In this study, the colonization and pathogenesis potential of S. Typhi and S. Paratyphi A in newborn and infant mice was evaluated. Newborn and infant mice were observed to be colonized by S. Typhi and S. Paratyphi A, but were tolerant of the infection. In addition, whether S. Typhi and S. Paratyphi A carrying and expressing the S. Typhimurium virulence plasmid were able to better infect and colonize newborn and infant mice was evaluated.

Methodology Bacterial strains and culture conditions

The bacterial strains and plasmids used in this study are listed in Table 1. Bacteriological media and components were from Difco (Franklin Lakes, NJ). Antibiotics and reagents were from Sigma (St. Louis, MO). Salmonella strains were grown at 37°C in either buffered magnesium minimal medium pH 5.5 (MgM) [32] or LB medium [33]. For plates, media was solidified with 1.5% (wt/vol) agar. When required, medium was supplemented with tetracycline (tet; 12.5 μg/ml), L-cysteine-HCl (cys; 22 μg/ml), DL-tryptophan (trp; 20 μg/ml) and L-histidine-HCl (his; 22 μg/ml). Buffered saline with gelatin (BSG) [34] was used as a diluent and to suspend bacteria prior to inoculation of mice.

Beta-galactosidase assays

Expression of spvR-lacZ and spvA-lacZ fusions in RpoS+ and RpoS−S. Typhi was determined by β-galactosidase activity assay [35]. Strains were transformed with pGTR72 (spvR-lacZ, operon fusion), pGTR90 (spvA-lacZ, operon fusion) or pGTR75 (tet-lacZ operon fusion control) [36] and grown in MgM medium to stationary phase. The spv operon is up-regulated under conditions that mimic the Salmonella containing vacuole (SCV) [33]. MgM media was used for this experiment because it mimics the environment of SCV [37].

Construction and characterization of <italic>S</italic>. Typhi and <italic>S</italic>. Paratyphi A carry pSTV

S Typhi and S. Paratyphi A strains harboring the S. Typhimurium virulence plasmid were constructed by conjugation on minimal media [38]. Plasmid pStSR101 is a Tnmini-tet-labeled virulence plasmid derivative, which can restore the full virulence of pSTV-cured strains of S. Typhimurium [25]. Like the wild-type virulence plasmid, it is self-transmissible [38]. S. Typhimurium χ3351 SL1344 hisG carrying pStSR101 was used as the donor. Conjugation was performed in M9 minimal media agar [39], supplemented with cys, trp, and his. Selection was performed on M9 media supplemented with cys, trp and tet to select for S. Typhi and S. Paratyphi A transconjugants and against the histidine-requiring S. Typhimurium donor. Transconjugants were characterized for LPS, Vi antigen (S. Typhi), biochemical properties, and nutritional requirements as described [39] and were found to exhibit the expected phenotypes (Table 1). The stability of pStSR101 in S. Typhi and S. Paratyphi A was determined essentially as described by Konjufca et al. [40], except that strains were grown in the absence of tetracycline for fifty generations, at which point cells were plated onto LB agar and individual colonies were screened for tetracycline resistance.

Reverse Transcriptase-PCR

Expression of spvR and spvA in S. Typhi and S. Paratyphi A from pStSR101 was evaluated by RT-PCR. Total RNA extraction was performed by RNeasy QIAgene kit (Hilden, Germany) from strains grown in MgM media at 37°C to stationary phase [33,37]. Reverse transcription and PCR was performed using the one-step RT-PCR QIAgene kit. Specific primers were used for the spvR (5′-GGAAACAGGTTCCTTCAGTATCGC-3′ and 5′-TATTTGGCTGTTAACGGCTCTCCC-3′) (size of the spvR amplified fragment: 349 bp) and spvA (5′-TTGTCCGTCAGACCCGTAAACAGT-3′ and 5′-TCTTCCAGCGACACATCGGTATT CAG-3′) (size of the spvA amplified fragment: 358 bp) genes. 16S rRNA primers were used as control of expression (5′-ACTGGCAGGCTTGAGCTTGTAGA-3′ and 5′-AAGGGCACAACCTCCAAGTA GACA-3′) (size of the 16S rRNA amplified fragment: 158 bp).

Animal experiments

BALB/c newborn and infant mice (Charles River Laboratories, Wilmington, MA) were bred and maintained at 22°C to 23°C with 12 hours of illumination daily. Mice older than two weeks were separated from their mothers 4 hours before infection and fed with regular food. Bacterial strains were grown overnight in standing cultures that were diluted 1:100 in prewarmed LB broth and grown with mild aeration to an OD600 of 0.8 to 0.9. Bacteria were sedimented by centrifugation at room temperature and resuspended in BSG to densities appropriate for the inoculation route and dose. Newborn mice (3 to 24 hours) and infant mice (48 hours to 3 weeks old) were challenged with ~109 CFU of S. Typhi, S. Paratyphi A, or S. Typhimurium. Ten microliters of ~109 CFU of the bacterial strain suspended in BSG were orally administered. Intranasal inoculations consisted in 5 μl of ~109 CFU of the bacterial strain suspended in BSG, administered without anesthesia. Mice were euthanized via asphyxiation with CO2 and necropsied at various times. The bacterial titers in newborn mice inoculated orally were determined at 3, 7, 14 and 21 days post oral infection. Spleen, liver, and the intestines were collected and washed with BSG until homogenization. The homogenizer (Brinkman, Westburg, NY) was washed with 5% Amphyl, followed by a wash with 70% ethanol, followed by two washes with dH2O. Homogenized tissues were plated onto MacConkey agar plates supplemented with 1% lactose to determine the number of viable bacteria. Salmonella colonies were white on the MacConkey plates. Isolated colonies were further identified by agglutination with Salmonella specific antiserum (Table 1) and antibiotic resistance marker.

Statistics

Mann-Whitney U Test (version 5.0; GraphPad Software, Inc.) was used for comparing the expression of spv-lacZ fusions.

Results Virulence and colonization of <italic>S.</italic> Typhi and <italic>S.</italic> Paratyphi A in newborn and infant mice

Newborn and infant mice infected orally with S. Typhi and S. Paratyphi A survived without any symptoms of disease, while the mice inoculated with a S. Typhimurium strain cured of plasmid pSTV succumbed to the infection (Table 2). Infant mice, one to three weeks of age, and newborn mice infected intranasally with S. Typhi and S. Paratyphi A strains also survived without any symptoms of disease (Table 2). The bacterial titers in newborn mice inoculated orally were determined at 3, 7, 14 and 21 days post infection. Spleen, liver, and the intestines were collected and the number of viable bacteria was determined. S. Typhi RpoS+ and S. Paratyphi A RpoS+ were able to colonize the intestines for three weeks (Figure 1A). S. Typhi Ty2 RpoS− was less able to persist in the intestines and cleared after one week. S. Typhi and S. Paratyphi A were able to colonize the spleen and liver of infected mice and the RpoS- strain Ty2 was more effectively cleared than the RpoS+ strains (Figures 1B and 1C). These results are consistent with a report that rpoS S. Typhimurium mutants are less persistent in mice than their wild-type RpoS+ parent strains [41, 45]. Taken together, these results show that although wild-type S. Typhi and S. Paratyphi A can transiently colonize young mice, they are not capable of establishing a disseminating infection.

Expression of spv genes in <italic>S.</italic> Typhi RpoS<sup>+</sup> and RpoS

The S. Typhimurium virulence plasmid is required for colonization of mouse tissues [24]. An investigation into whether the addition of the virulence plasmid to S. Typhi and S. Paratyphi A could enhance their ability to colonize young mice was conducted. One virulence plasmid operon that is critical for host invasion is encoded in the spv region [24,33,46]. The spv region consists of five genes, spvRABCD which are all transcribed in the same direction [46]. The spvR gene encodes SpvR, which activates the transcription of both the spvR and spvABCD transcriptional units [12,47,48]. In addition, the sigma factor RpoS is also required for maximum expression of the operon [49,50,51,52].

Because of the central role of spv in tissue colonization, expression of spvR-lacZ and spvA-lacZ fusions in RpoS+ and RpoS− S. Typhi by β-galactosidase activity were compared to establish that these genes were able to be transcribed in S. Typhi and that transcription is dependent upon RpoS. [35]. The RpoS+ S. Typhi strains produced β-galactosidase levels comparable to the S. Typhimurium RpoS+ control for both fusions (Figures 2A and 2B). In contrast, reduced expression was observed for S. Typhi Ty2, which has a defective rpoS allele due to a frame-shift mutation at nucleotide 993 [53]. These results indicate that S. Typhi is able to transcribe the spv genes to the same levels as S. Typhimurium and confirm that maximum spv expression requires RpoS.

Stability and expression of pSTV plasmid in <italic>S.</italic> Typhi and <italic>S.</italic> Paratyphi A

A tetracycline-marked derivative of the S. Typhimurium virulence plasmid, pStSR101 [24], was moved into the S. Typhi and S. Paratyphi A strains. Because these host-restricted strains do not normally carry this plasmid, it is possible that the plasmid may not be maintained for enough generations to colonize a mouse. Therefore, the stability of pStSR101 in S. Typhi and S. Paratyphi A was examined. The pStSR101 virulence plasmid was stably maintained for 50 or more generations in all S. Typhi and S. Paratyphi A strains. In addition, whether the spv genes were transcribed from this plasmid was evaluated. RT-PCR products were detected in all strains harboring pStSR101 (Figure 3), indicating that the spv genes are transcribed in S. Typhi and S. Paratyphi A.

Virulence and colonization of <italic>S</italic>. Typhi and <italic>S.</italic> Paratyphi A harboring pSRSt101 in newborn and infant mice

The effect of the S. Typhimurium virulence plasmid on the ability of S. Typhi and S. Paratyphi A to cause disease in newborn and infant mice was evaluated. When newborn and infant mice were orally inoculated with S. Typhi and S. Paratyphi A harboring pStSR101, they survived without any disease symptoms, whereas all the mice inoculated with S. Typhimurium died (Table 3). Infant mice and newborn mice infected intranasally with S. Typhi or S. Paratyphi A carrying pStSR101 also survived without any symptoms of disease (Table 3).

The presence of pStSR101 did not enhance the ability of S. Typhi and S. Paratyphi A to colonize infant mice (Figure 1). Unexpectedly, the presence of pStSR101 in S. Typhi Ty2 RpoS− resulted in a slight increase in persistence in the intestines compared to the plasmid-free strain (Figures 1A and 1D), indicating that there may be a virulence plasmid gene(s) that can complement the defect in intestinal colonization imparted by the RpoS− phenotype. Recently, it has been reported that pPST98, a promiscuous R plasmid found in a multi-drug resistant isolate of S. Typhi from Asia, carries the spv region. This plasmid confers antibiotic resistance and increases virulence in mice when transferred to pSTV− S. Typhimurium [54]. While it is possible that spv genes may confer an enhancement of virulence in human hosts, our results indicate that they have no effect on infant mouse colonization in wild-type S. Typhi.

Discussion

In summary, these results show that S. Typhi and S. Paratyphi A can transiently colonize young mice, but cannot establish a lethal infection. The spv genes are transcribed in S. Typhi and S. Paratyphi A and a functional rpoS gene is required for maximum expression. However, the virulence plasmid does not enable S. Typhi or S. Paratyphi A to establish a lethal infection in newborn or infant mice.

This work was supported by grants from the National Institutes of Health (AI24533, AI057885, AI056289) and the Bill and Melinda Gates Foundation (#37863 and CONICYT), Chile, through Gestión Propia Fellowship.

We are grateful to Dr. Paul Gulig (University of Florida, USA) for providing the pGTR73, pGTR75 and pGRT90 plasmids and advice. We are particularly grateful to Dr. James Robeson (Pontifícia Universidad Católica de Valparaíso, Chile), and Dr. Kenneth Roland (Biodesign Institute at Arizona State University, USA) for their suggestions.

Conflict of interests: No conflict of interests is declared.

Parry CM Hien TT Dougan G White NJ Farrar JJ 2002 Typhoid fever N Engl J Med 2002 347 1770 1782 Sood S Kapil A Dash N Das BK Goel V Seth P 1999 Paratyphoid fever in India: An emerging problem Emerg Infect Dis 5 483 484 10341194 Curtiss R III Mestecky J Bienenstock J Lamm ME Mayer L McGhee JR Strober W 2005 Antigen delivery systems: Development of live recombinant attenuated bacterial antigen and DNA vaccine delivery vector vaccines Mucosal Immunology 3 Academic Press New York 1009 1037 Dietrich G Spreng S Gentschev I Goebel W 2000 Bacterial systems for the delivery of eukaryotic antigen expression vectors Antisense Nucleic Acid Drug Dev 10 391 399 11079578 Garmory HS Brown KA Titball RW 2002 Salmonella vaccines for use in humans: present and future perspectives FEMS Microbiol Rev 26 339 353 12413664 Edsall G Gaines S Landy M Tigertt WD Sprinz H Trapani RJ Mandel AD Benenson AS 1960 Studies on infection and immunity in experimental typhoid fever. I. Typhoid fever in chimpanzees orally infected with Salmonella typhosa J Exp Med 112 143 166 13725751 Pasetti MF Levine MM Sztein MB 2003 Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors Vaccine 21 401 418 12531639 Carter PB Collins FM 1974 Growth of typhoid and paratyphoid bacilli in intravenously infected mice Infect Immun 10 816 822 4214784 Carter PB Collins FM 1974 The route of enteric infection in normal mice J Exp Med 139 1189 1203 4596512 Collins FM Carter PB 1978 Growth of Salmonellae in orally infected germfree mice Infect Immun 21 41 77 361568 Gerichter CB 1960 The dissemination of Salmonella typhi, S. paratyphi A and S. paratyphi B through the organs of the white mouse by oral infection J Hyg (Lond) 58 307 319 13704606 Sheehan BJ Dorman CJ 1998 In vivo analysis of the interactions of the LysR-like regulator SpvR with the operator sequences of the spvA and spvR virulence genes of Salmonella typhimurium Mol Microbiol 30 91 105 9786188 Nugester WJ Jourdonais LF Wolf AA 1936 The effect of mucin on infections by bacteria J Infect Dis 1936 59 11 Powell CJ Jr DeSett CR Lowenthal JP Berman S 1980 The effect of adding iron to mucin on the enhancement of virulence for mice of Salmonella typhi strain TY2 J Biol Stand 8 79 85 6156943 Spaun J 1964 Studies on the influence of the route of immunization in the active mouse protection test with intraperitoneal challenge for potency assay of typhoid vaccines Bull World Health Organ 31 793 798 14277258 Baker SJ Daniels C Morona R 1997 PhoP/Q regulated genes in Salmonella typhi identification of melittin sensitive mutants Microb Pathog 1997 22 165 179 Gilman RH Young C Bulger R Hornick RB Greenberg B 1982 Anatomical and immunological responses of rabbit gallbladders to bacterial infections Infect Immun 36 407 416 6804393 Metcalf ES Almond GW Routh PA Horton JR Dillman RC Orndorff PE 2000 Experimental Salmonella typhi infection in the domestic pig, Sus scrofa domestica Microb Pathog 29 121 126 10906267 Galen JE Gomez-Duarte OD Losonsky GA Halpern JL Lauderbaugh CS Kaintuck S Reymann MK Levine MM 1997 A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens Vaccine 15 700 708 9178472 Pickett TE Pasetti MF Galen JE Sztein MB Levine MM 2000 In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors Infect Immun 68 205 213 10603389 Bäumler AJ Tsolis RM Ficht TA Adams LG 1998 Evolution of host adaptation in Salmonella enterica Infect Immun 66 4579 4587 9746553 Jones BD Falkow S 1996 Salmonellosis: host immune responses and bacterial virulence determinants Annu Rev Immunol 14 533 561 8717524 McClelland M Sanderson KE Clifton SW Latreille P Porwollik S Sabo A Meyer R Bieri T Ozersky P McLellan M Harkins CR Wang C Nguyen C Berghoff A Elliott G Kohlberg S Strong C Du F Carter J Kremizki C Layman D Leonard S Sun H Fulton L Nash W Miner T Minx P Delehaunty K Fronick C Magrini V Nhan M Warren W Florea L Spieth J Wilson RK 2004 Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid Nat Genet 36 1268 1274 15531882 Fang FC Krause M Roudier C Fierer J Guiney DC 1991 Growth regulation of a Salmonella plasmid gene essential for virulence J Bacteriol 173 6783 6789 1938884 Gulig PA Curtiss R III 1987 Plasmid-associated virulence of Salmonella typhimurium Infect Immun 55 2891 2901 3316027 Korpela K Ranki M Sukupolvi S Makela H Rhen M 1989 Occurrence of Salmonella typhimurium virulence plasmid-specific sequences in different serovars of Salmonella FEMS Microbiol Lett 58 49 54 2656397 Parkhill J Dougan G James KD Thomson NR Pickard D Wain J Churcher C Mungall KL Bentley SD Holden MT Sebaihia M Baker S Basham D Brooks K Chillingworth T Connerton P Cronin A Davis P Davies RM Dowd L White L Farrar J Feltwell T Hamlin N Haque A Hien TT Holroyd S Jagels K Krogh A Larsen TS Leather S Moule S O’Gaora P Parry C Quail M Rutherford K Simmonds M Skelton J Stevens K Whitehead S Barrell BS 2001 Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18 Nature 413 848 852 11677608 Poppe C Curtiss R III Gulig PA Gyles CL 1989 Hybridization studies with a DNA from the virulence region of the 60 Mdal plasmid of Salmonella typhimurium Can J Vet Res 53 378 384 2686827 Chaicumpa W Rowley D 1972 Experimental cholera in infant mice: protective effects of antibody J Infect Dis 125 480 485 5023642 Guentzel MN Berry LJ 1975 Motility as a virulence factor for Vibrio cholerae Infect Immun 11 890 897 1091563 Ujiiye A Kobari K 1970 Protective effect on infections with Vibrio cholerae in suckling mice caused by the passive immunization with milk of immune mothers J Infect Dis 121 Suppl S50 S55 Hmiel SP Snavely MD Miller CG Maguire ME 1986 Magnesium transport in Salmonella typhimurium: characterization of magnesium influx and cloning of a transport gene J Bacteriol 168 1444 1450 3536881 Mazurkiewicz P Thomas J Thompson JA Liu M Arbibe L Sansonetti P Holden DW 2008 SpvC is a Salmonella effector with phosphothreonine lyase activity on host mitogen-activated protein kinases Mol Microbiol 67 1371 1383 18284579 Curtiss R III 1965 Chromosomal aberrations associated with mutations to bacteriophage resistance in Escherichia coli J Bacteriol 89 28 40 14255678 Miller JH 1972 Experiments in molecular genetics Could Spring Harbor Laboratory Cold Spring Harbor, New York Bertani G 1951 Studies on lysogenesis. I The mode of phage liberation by lysogenic Escherichia coli J Bacteriol 62 293 300 14888646 Wilson JA Doyle TJ Gulig PA 1997 Exponential-phase expression of spvA of the Salmonella typhimurium virulence plasmid: induction in intracellular salts medium and intracellularly in mice and cultured mammalian cells Microbiology 143 3827 3839 9421907 Ahmer BM Tran M Heffron F 1999 The virulence plasmid of Salmonella typhimurium is self-transmissible J Bacteriol 181 1364 1368 9973370 Sambrook J Russell W 2001 Molecular Cloning; A Laboratory Manual 3 Cold Spring Harbor Press Konjufca V Wanda SY Jenkins MC Curtiss RIII 2006 A recombinant attenuated Salmonella enterica serovar Typhimurium vaccine encoding Eimeria acervulina antigen offers protection against E. acervulina challenge Infect Immun 74 6785 6796 16982843 Santander J Wanda SY Nickerson CA Curtiss RIII 2007 Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in Salmonella enterica serotype Typhi Infect Immun 75 1382 1392 17178790 Curtiss R III Porter SB Munson M Tinge SA Hassan JO Gentry-Weeks C Kelly SM Blankenship LC Bailey JS Cox NA Stern NJ Meinersmann RJ 1991 Nonrecombinant and recombinant avirulent Salmonella live vaccines for poultry Colonization control of human bacterial enteropathogens in poultry Academic Press New York 169 198 Felix A Pitt RM 1951 The pathogenic and immunogenic activities of Salmonella typhi: in relation to its antigenic constituents J Hyg 49 92 110 20475842 Caldwell AL Gulig PA 1991 The Salmonella typhimurium virulence plasmid encodes a positive regulator of a plasmid-encoded virulence gene J Bacteriol 173 7176 7185 1657882 Coynault C Robbe-Saule V Norel F 1996 Virulence and vaccine potential of Salmonella typhimurium mutants deficient in the expression of the RpoS (sigma S) regulon Mol Microbiol 22 149 160 8899717 Gulig PA Caldwell AL Chiodo VA 1992 Identification, genetic analysis and DNA sequence of a 7.8-kb virulence region of the Salmonella typhimurium virulence plasmid Mol Microbiol 6 1395 1411 1322485 Coynault C Robbe-Saule V Popoff MY Norel F 1992 Growth phase and SpvR regulation of transcription of Salmonella typhimurium spvABC virulence genes Microb Pathog 13 133 143 1453926 Krause M Fang FC Guiney DG 1992 Regulation of plasmid virulence gene expression in Salmonella dublin involves an unusual operon structure J Bacteriol 174 4482 4489 1378053 Kowarz L Coynault C Robbe-Saule V Norel F 1994 The Salmonella typhimurium katF (rpoS) gene: cloning, nucleotide sequence, and regulation of spvR and spvABCD virulence plasmid genes J Bacteriol 176 6852 6860 7961444 Nickerson CA Curtiss R III 1997 Role of sigma factor RpoS in initial stages of Salmonella typhimurium infection Infect Immun 65 1814 1823 9125566 Norel F Robbe-Saule V Popoff MY Coynault C 1992 The putative sigma factor KatF (RpoS) is required for the transcription of the Salmonella typhimurium virulence gene spvB in Escherichia coli FEMS Microbiol Lett 1992 78 271 276 Valone SE Chikami GK Miller VL 1993 Stress induction of the virulence proteins (SpvA, -B, and -C) from native plasmid pSDL2 of Salmonella dublin Infect Immun 61 705 713 8380798 Robbe-Saule V Norel F The rpoS mutant allele of Salmonella typhi Ty2 is identical to that of the live typhoid vaccine Ty21a 1999 FEMS Microbiol Lett 170 141 143 9919662 Huang R Wu S Zhang X Zhang Y 2005 Molecular analysis and identification of virulence gene on pRST98 from multi-drug resistant Salmonella typhi Cell Mol Immunol 2 136 140 16191420

Colonization of S. Typhi and S. Paratyphi A with and without pStSR101 virulence plasmid in newborn mice < 24 h old. A–C. Newborn mice orally infected with Salmonella without pStSR101; D–F. Newborn mice orally infected with Salmonella harboring pStSR101; A, D. Intestine colonization; B, E. Spleen colonization; C, F. Liver colonization. Each point represents the average between 4 animal tissues.

Evaluation of spvR and spvA expression in S. Typhi by β-galactosidase assay. A. Evaluation of spvR; B. Evaluation of spvA; C. Control. χ3769 S. Typhi Ty2 RpoS−; χ3744 S. Typhi ISP1820 RpoS+; χ3337 S. Typhimurium SR-11 RpoS+; strains harboring the respective plasmids; the strains where grown in MgM media to stationary growth phase. *P<0.01 for the RpoS+ strains compared with RpoS− strain, significant differences are indicated.

Expression of spvR and spvA evaluated by RT-PCR (agarose gel 1%). 1. χ3769 S. Typhi Ty2; 2. χ3744 S. Typhi ISP1820; 3. χ8387 S. Paratyphi A; 4. χ3769 S. Typhi Ty2 (pStSR101); 5. χ3744 S. Typhi ISP1820 (pStSR101); 6. χ8387 S. Paratyphi A (pStSR101); 7. χ3351 S. Typhimurium SL-1344 (pStSR101); 8. χ3761 S. Typhimurium UK-1 pSTV+; 16S: 16S (rrnA) was used as positive control; DNA control: the RNA samples were used as templates in a PCR reaction to amplify the 16SrRNA to detect DNA contamination.

Salmonella strains and relevant characteristics

Strain Relevant characteristics Origin Source or reference
χ3744 S. Typhi ISP1820 Wild-type, RpoS+, Cys−, Trp−, OD1:Hd:-:Vi, V & V/W form Wild-type 41
χ3744 S. Typhi ISP1820 (pStSR101) Wild-type RpoS+, Cys−, Trp−, OD1:Hd:-:Vi, V & V/W form, Tetr χ3744 This study
χ3761 S. Typhimurium UK-1 RpoS+, pSTV, OB1:Hi:H2:- Wild-type 42
χ3769 S. Typhi Ty2 Wild-type, RpoS−, Cys−, OD1:Hd:-:Vi, V form Wild-type 43
χ3769 S. Typhi Ty2 (pStSR101) Wild-type, RpoS−, Cys−, OD1:Hd:-:Vi, V form, Tetr χ3769 This study
χ8219 S. Paratyphi A RpoS+, Cryptic plasmid pSPA1, OA:Ha:-:- Wild-type ATCC 9281
χ8387 S. Paratyphi A RpoS+, Cryptic plasmid cured, OA:Ha:-:- χ8219 This study
χ8387 S. Paratyphi A (pStSR101) RpoS+, OA:Ha:-:-, Tetr χ8387 This study
χ8438 S. Typhi Ty2 RpoS+, Cys−, OD1:Hd:-:Vi, V & V/W form χ3769 41
χ8438 S. Typhi Ty2 (pStSR101) RpoS+, Cys−, OD1:Hd:-:Vi, V & V/W form, Tetr χ8438 This study
χ8740 S. Typhi CT18 RpoS+, Vi−, OD1:Hd:-:-, W form Wild-type 27
χ3337 S. Typhimurium SR-11 RpoS+, gyrA1816, pSTV−, OB1:Hi:H2:- χ3306 25
χ3351 S. Typhimurium SL-1344 (pStSR101) RpoS+, rpsL, hisG, Tetr, OB1:Hi:H2:- χ3340 25
Plasmids
pGTR72 spvR-lacZ,cat 44
pGTR90 spvA-lacZ,cat 44
pGTR75 spvR::lacZ,cat cat, same as pGTR72, except the lacZ,cat is inserted in opposite orientation, under control of tet promotor of the plasmid 44
pSTV spvRABCD, pefBACD, rck 25
pStSR101 spvRABCD, pefBACD, rck, Tnmini-tet- 25

Infection of newborn and infant mice with S. Typhi and S. Paratyphi A.

Strain Inoculating dose (CFU) Mice age Survivors/total Route
χ3744 S. Typhi ISP1820 1.1 x 109 3 weeks 5/5 oral
1.1 x 109 1 week 7/7 oral
1.1 x 109 <24 h 6/6 oral
1.1 x 109 1 week 7/7 intranasal
χ3769 S. Typhi Ty2 (RpoS−) 1.1 x 109 <24 h 5/5 oral
χ8438 S. Typhi Ty2 (RpoS+) 1.5 x 109 <24 h 4/4 oral
χ8740 S. Typhi CT18 1.0 x 109 <24 h 8/9 oral
χ8387S. Paratyphi A 1.1 x 109 <24 h 8/8 oral
1.1 x 109 1 week 9/9 intranasal
χ3337 S. Typhimurium SR-11 2.1 x 109 3 weeks 0/5 oral
2.1 x 109 <24 h 0/5 oral

Newborn: 3 h to 24 h after birth. Infant: 48 h to 3 weeks old. Mice were observed for 4–5 weeks.

χ3337 S. Typhimurium pSTV-cured was used as positive control.

Infection of newborn and infant mice with S. Typhi pStSR101 and S. Paratyphi A pStSR101.

Strain Inoculating dose (CFU) Mice age Survivors/total Route
χ3744 S. Typhi ISP1820 (pStSR101) 1.2 x 109 <24 h 6/6 oral
1.1 x 109 <24 h 7/7 intranasal
χ3769 S. Typhi Ty2 (pStSR101) 1.2 x 109 <24 h 5/5 oral
χ8387 S. Paratyphi A (pStSR101) 1.1 x 109 <24 h 10/10 oral
1.1 x 109 <24 h 7/7 intranasal
χ3351 S. Typhimurium SL-1344 (pStSR101) 1.8 x 109 3 weeks 0/5 oral
1.8 x 109 <24 h 0/8 oral

Newborn: 3 h to 24 h after birth. Infant: 48 h to 3 weeks old. Mice were observed between 4–5 weeks.

χ3351 S. Typhimurium (pStSR101) was used as positive control.